- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01429714
The Ideal Deep Venous Thrombosis (DVT) Study (IDEAL)
Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial
In the Netherlands, 25.000 patients each year are diagnosed with Deep Venous Thrombosis (DVT). Elastic compression stocking (ECS) therapy reduces the incidence of post thrombotic syndrome (PTS) following DVT from 50% without ECS to 20-30% after ECS therapy for two years. It is however unclear whether all patients benefit to the same extent from this therapy or what the optimal duration of ECS therapy for individual patients should be. ECS therapy is not only costly, inconvenient and demanding but sometimes also even debilitating. Substantial costs could be saved by tailoring therapy to individual needs and as a result the quality of life for individual patients can be expected to improve.
This study aims to assess the costs and effects of tailoring the duration of ECS therapy after DVT to individual patients needs.
ECS therapy with a standard duration of 24 months will be compared with tailored ECS therapy, following an initial therapeutic period of 6 months, in patients with acute proximal DVT. The primary outcome is the percentage of patients with PTS at two year follow-up.
This is a multi-center, randomized, allocation concealed, single-blinded clinical trial.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Almere, Holland, 1315 RA
- FlevoHospital
-
Amsterdam, Holland, 1066 EC
- Slotervaart Hospital
-
Amsterdam, Holland, 1105 AZ
- AMC
-
Amsterdam, Holland, 1091 AC
- OLVG
-
Amsterdam, Holland, 1007 MB
- VU Medical Centre
-
Eindhoven, Holland, 5631 BM
- Maxima Medical Centre
-
Groningen, Holland, 9713 GZ
- UMCG
-
Heerlen, Holland, 6419 PC
- Atrium Medical Centre
-
Hoorn, Holland, 1091 AC
- Westfriesgasthuis
-
Maastricht, Holland, 6202 AZ
- Maastricht University Medical Centre
-
Nijmegen, Holland, 6525 GA
- UMC Nijmegen Radboud
-
Roermond, Holland, 6043 CV
- Laurentius Ziekenhuis
-
-
-
-
-
Padua, Italien, 35128
- Azienda Ospedaliera di Padova
-
Treviso, Italien
- Treviso Aziende
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Legal age (18 yrs)
- Informed consent
- Acute objectively documented DVT of the leg
- Adequate anticoagulation
Exclusion Criteria:
- Previous DVT in the affected leg
- Recurrent DVT in the first 6 months following inclusion
- Preexistent venous insufficiency (skin signs C4-C6 on CEAP score or requiring ECS therapy)
- Contraindication for elastic compression therapy (arterial insufficiency)
- Active thrombolysis
- Life expectancy < 6 months
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention: individually tailored ECS
Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
|
Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
Andre navne:
|
|
Aktiv komparator: Control: ECS 24 months
Elastic compression therapy with a standard duration of 24 months
|
Elastic compression therapy with a standard duration of 24 months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The occurrence of PTS at 24 months after the event of acute DVT
Tidsramme: At 24 months after the event of the acute DVT
|
At 24 months after the event of the acute DVT
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Related Quality of Life (HRQOL)
Tidsramme: Baseline, 3, 6, 12 and 24 months
|
HRQOL, will be measured by questionnaires SF-36, EuroQol-5D, Veines-Qol Dutch translated
|
Baseline, 3, 6, 12 and 24 months
|
|
Recurrent venous thrombosis
Tidsramme: 24 months
|
24 months
|
|
|
Mortality due to venous thrombosis
Tidsramme: 24 months
|
24 months
|
|
|
Costs
Tidsramme: 3, 6, 12, 24 months
|
Costs will include direct costs (e.g.
medical therapy) and indirect costs (e.g.
travel) and will be measured by case record forms, hospital data and 5 retrospective cost-questionnaires
|
3, 6, 12, 24 months
|
|
Patient Preferences
Tidsramme: baseline, 24 months
|
Patient preferences will be elicited by conducting a discrete choice experiment (DCE)
|
baseline, 24 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Arina J ten Cate-Hoek, MD, PhD, MpH, Maastricht University Medical Centre
Publikationer og nyttige links
Generelle publikationer
- Ten Cate-Hoek AJ, Bouman AC, Joore MA, Prins M, Ten Cate H; IDEAL DVT trial investigators. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open. 2014 Sep 4;4(9):e005265. doi: 10.1136/bmjopen-2014-005265.
- Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S, Mostard GJM, Ten Wolde M, van den Heiligenberg SM, van Wissen S, van de Poel MH, Villalta S, Serne EH, Otten HM, Klappe EH, Bistervels IM, Lauw MN, Piersma-Wichers M, Prandoni P, Joore MA, Prins MH, Ten Cate H; IDEAL DVT investigators. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol. 2018 Jan;5(1):e25-e33. doi: 10.1016/S2352-3026(17)30227-2. Epub 2017 Dec 5.
- Amin EE, Ten Cate-Hoek AJ, Bouman AC, Meijer K, Tick L, Middeldorp S, Mostard G, Ten Wolde M, van den Heiligenberg S, van Wissen S, van de Poel M, Villalta S, Serne E, Otten HM, Klappe E, Prandoni P, Prins MH, Ten Cate H, Joore MA. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematol. 2018 Nov;5(11):e512-e519. doi: 10.1016/S2352-3026(18)30151-0. Epub 2018 Oct 9.
- Amin EE, Bistervels IM, Meijer K, Tick LW, Middeldorp S, Mostard G, van de Poel M, Serne EH, Otten HM, Klappe EM, Joore MA, Ten Cate H, Ten Wolde M, Ten Cate-Hoek AJ. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood. 2018 Nov 22;132(21):2298-2304. doi: 10.1182/blood-2018-03-836783. Epub 2018 Sep 20.
- Amin EE, Joore MA, Ten Cate H, Meijer K, Tick LW, Middeldorp S, Mostard GJM, Ten Wolde M, van den Heiligenberg SM, van Wissen S, van de Poel MHW, Villalta S, Serne EH, Otten HM, Klappe EH, Prandoni P, Ten Cate-Hoek AJ. Clinical and economic impact of compression in the acute phase of deep vein thrombosis. J Thromb Haemost. 2018 Jun 1. doi: 10.1111/jth.14163. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdom
- Embolisme og trombose
- Perifere vaskulære sygdomme
- Venøs insufficiens
- Phlebitis
- Syndrom
- Trombose
- Venøs trombose
- Posttrombotisk syndrom
- Postflebitisk syndrom
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Adrenerge alfa-agonister
- Adrenerge agonister
- Respiratoriske midler
- Sympatomimetika
- Vasokonstriktormidler
- Nasale dekongestanter
- Oxymetazolin
Andre undersøgelses-id-numre
- 10-2-026
- 80-82310-97-11017 (Andet bevillings-/finansieringsnummer: ZonMw)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Posttrombotisk syndrom
-
GlaxoSmithKlineIkke rekrutterer endnu
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCRekrutteringStickler syndrom type 2 | Stickler syndrom type 1Forenede Stater
-
Unravel Biosciences, Inc.RekrutteringPitt Hopkins syndromColombia
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Riphah International UniversityAfsluttet
-
Haleema SadiaAfsluttetPræmenstruelt syndrom - PMSPakistan
-
Esra ÖZERKTO Karatay UniversityAfsluttetEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun